We have previously shown that immunization with solid matrix-antigen-antibody (SMAA) complexes induces both vigorous humoral and cell-mediated immune responses and have suggested that this method of vaccination may be developed for use in humans, and potentially as a vaccine against AIDS. Here we demonstrate that a small oligopeptide can act as a tag for the construction of SMAA complexes using a tagspecific monoclonal antibody and tag-linked antigens. We show that a 14-amino acid oligopeptide, present in the phospho (P) and V proteins of simian virus 5 (SV5), retains its antigenicity when attached to the C terminus of three 'foreign' proteins [p27 and gp110 of simian immunodeficiency virus (SIV) and glutathione S-transferase] such that these proteins can be incorporated into SMAA complexes using a monoclonal antibody (MAb) that was originally raised against the native SV5 P and V proteins. Mice were immunized with SMAA complexes containing recombinant p27-TAG and MAbs have been isolated that recognized native SIV p27. The significance of these results in terms of the development of SMAA complexes as human vaccines is discussed.
Introduction
The spread of many viral diseases has been controlled through vaccination programmes that use 'killed' or live attenuated virus vaccines. Nevertheless in certain instances a number of problems have been encountered with such vaccines, and for other virus diseases these approaches have not proved successful (for review see Randall & Souberbielle, 1990) . A great effort is therefore being made to develop alternative vaccination strategies and to improve the efficacy and safety of existing vaccines. These interventions, however, require a thorough understanding of the basis of immune responses to virus infections as well as of the biology of virus replication. The current AIDS pandemic has demonstrated painfully how much we have yet to learn about the molecular processes underlying virus-host interactions. Indeed the development of successful vaccines to human immunodeficiency virus, the causative agent of AIDS, still remains one of the most challenging goals facing modern molecular virology and immunology.
We have suggested that the construction of solid matrix-antibody-antigen (SMAA) complexes may be a means of producing effective antiviral vaccines (Randall, 1989) . In this approach particulate solid matrices are saturated with specific monoclonal antibodies (MAbs), which in turn are saturated with their respective antigens. The resulting SMAA complexes are used as immunogens. Such complexes are highly immunogenic inducing both vigorous humoral and cellmediated immune responses . Multispecific immunization with SMAA complexes has been achieved either by incorporating different virus antigens into the same SMAA complex using a mixture of MAbs (Randall & Young, 1989) or by making monospecific SMAA complexes and mixing them prior to injection. Immunization of mice with SMAA complexes that contain either internal or external structural proteins of the paramyxovirus, simian virus 5 (SV5), enhances the speed of clearance of virus from immunized mice . The effector cells primarily responsible for virus clearance were shown to be CD8 ÷ lymphocytes and the demonstration that SMAA complexes induced class I-restricted cytotoxic T cells (as measured in vitro) suggested that the effector cells responsible for the clearance of virus in vivo were indeed CD8 ÷ cytotoxic T cells . This set of experiments demonstrated that antigens introduced on SMAA complexes, i.e. non-infectious exogenous agents, can enter intracellular processing pathways leading to an induction of major histocompatibility complex class I-restricted T lymphocytes.
The ability to induce both branches of immunity significantly increases the attractiveness of SMAA complexes as potential prophylactic and therapeutic vaccines. To date we have only used mouse MAbs in the construction of SMAA complexes. It is unlikely that it will be possible to use mouse MAbs for producing vaccines for general use in humans. However, the crossspecies immunogenicity of MAbs included in SMAA complexes can be minimized or completely abolished by construction of genetically engineered human/rodent chimeric or reshaped antibodies, the latter of which contain only rodent antigen-specific complementarity determining regions grafted on a human framework (for review see Winter & Milstein, 1991 ). An economic approach to construction of SMAA complexes would be to employ a single 'humanized' MAb specific for a small universal peptide tag antigen, used to present any protein to which the tag antigen was attached. Furthermore, the possible use of Fab or Fv fragments for construction of SMAA complexes would enable a largescale production of these fragments using bacterial expression systems (Boulot et al., 1990; Skerra et al., 1991) , thus avoiding a laborious and expensive production of whole human antibodies in rat myeloma cell lines (Reichmann et al., 1988; Verhoeyen et al., 1988; Tempest et al., 1991) .
As a stage in the development of SMAA complexes as human vaccines, we show here that such an approach is feasible by identifying a small tag antigen of 14 amino acids which retains its antigenicity when coupled to the carboxyl termini of a variety of proteins and that such proteins can be incorporated into SMAA complexes using a MAb specific for the tag antigen. Using tagassembled SMAA complexes for immunization, we have isolated MAbs specific for simian immunodeficiency virus (SIV) p27.
Methods
Construction of plasmids. Plasmid pBK28-SIV (Kornfield et al., 1987) was kindly provided through the MRC AIDS Reagent Project. SIV genes were amplified by polymerase chain reaction (PCR) using the following primers: p27BACK (5' GCTCAGTGATCAATGCCAGT-ACAACAAATAGGT 3% p27FOR (5' GAGACAGGATCCTAAT-CTTGCCTTCTGTCCTGG Y), gpll0BACK (5' CATGTATGAT-CAATGGGATGTCTTGGGATTCAG Y) and gp110FOR (5' CGT-GATGGATCCTCTTTTATTTCTTGAGGTGCC 3'). The underlined sequences correspond to nucleotides 1446 to 1463 and 2108 to 2339 of the p27 gene and to nucleotides 6580 to 6600 and 8140 to 8162 of the gp 110 gene of SIV (macaque) proviral DNA, isolate Mm251, clone BK28 as in the GenBank database (P. R. Donahue, H. Kornfeld, R. C. Gallo & J, Mullins, unpublished results). Oligonucleotides used in this work were synthesized using an Applied Biosystems oligonucleotide synthesizer and phosphoramidite chemistry. Enzymes used for recombinant DNA work were purchased from Amersham or Bethesda Research Laboratories and used according to the vendors' recommendations. Plasmids were treated by standard protocols (Maniatis et al., 1982) . Escherichia coli strain DH 1 was made competent using the RbC1 method of Kushner (1978) . Plasmids were isolated using the alkaline lysis method of Birnboim & Doly (1979) .
Expression and purification of p27-TAG and GST-TAG. Glutathione S-transferase (GST) fusion proteins were prepared as described by Smith & Johnson (1988) with minor modifications. Briefly, bacteria carrying plasmids pGEX27T or pGEXTAG were grown to an OD60 o of 0-6 to 0.9 and the expression of the fusion proteins was induced by 1 mM-isopropyl-fl-D-thiogalactopyranoside (IPTG) at room temperature for 3 to 6 h. Bacteria were pelleted, washed in PBS, treated with 10 mg/ml of tysozyme, incubated in immune precipitation buffer (IPB; 20 mM-Tris-HC1 pH 7.2, 5 mM-EDTA, 0-5% NP40, 0.1~ SDS and 0-65 M-NaC1) and sonicated. Bacterial lysates were then centrifuged at 125000 g for 30 min. The supernatants were either used directly for production of SMAA complexes or applied onto a glutathione-agarose bead column (sulphur-linked, Sigma). For GST-p27-TAG purification, the supernatant was incubated with glutathione beads rotating end over end at 4 °C for 1 h. The beads were then loaded into a column, thoroughly washed with IPB and PBS and incubated with human thrombin (Sigma) to cleave off p27-TAG. Thrombin-released p27-TAG was eluted from the column by 2 column volumes of PBS. For the preparation of GST-TAG, adsorbed GST-TAG protein was eluted from the column by competition with 1 bead volume of freshly prepared 5 mM-reduced glutathione (Sigma) dissolved in 50 mM-Tris-HC1 pH 7.6.
Antibodies and cells. MAb SV5-P-k recognizing an epitope on SV5 phospho (P) and V proteins was isolated in our laboratory and used as a tag-specific antibody. Monoclonal anti-SIV p27 antibody KK33 (K. Kent, unpublished results) was obtained through the MRC AIDS Reagent Project. The SIVma~251 (32H)-infected C8166 cell line was a generous gift from Dr M. Cranage, CAMR, Porton Down, U.K.
Production of SMAA complexes. SMAA complexes were prepared as described before . Briefly, a 10% (w/v) suspension of 'fixed' and killed Cowan A strain of Staphylococcus aureus (Kessler, 1975) was incubated with an equal volume of SV5-P-k antibody-containing ascitic fluids at 4°C for 1 h. Unadsorbed antibodies were removed by three consequent pelletings (2500 g for 2 min) and resuspended in IPB. Antibody-saturated S. aureus was mixed with either purified p27-TAG at 4 °C for 1 h and washed as above, or added to bacterial lysates containing GST-p27-TAG and incubated end over end at 4 °C for 1 h. Complexes containing GSTp27-TAG were washed as above, treated with human thrombin in order to cleave off the GST domain and washed as in the previous steps. SMAA complexes were analysed by 15% SDS-PAGE or resuspended at 0.5 % (w/v) in sterile PBS for immunization of animals.
SDS-PAGE and Western blot analysis.
Polypeptide samples were suspended in the appropriate volume of 4 × disruption buffer (20% glycerol, 200 mM-Tris-HC1 pH 7, 20 % 2-mercaptoethanol, 8 % SDS and 0.25% bromophenol blue), boiled for 5 min and analysed on SDS-PAGE gels cross-linked with 15 % N,N'-diallyltartardiamide (DATD) using thin (0.4 mm) mini-slab gels of the Uniscience electrophoresis system. Separated polypeptides were either stained with Coomassie blue R-250 or transferred onto a nitrocellulose filter using a semi-dry gel electroblotter (LKB). The filters were blocked with 20% Marvel/PBS, incubated with SV5-P-k or KK33 ascitic fluids followed by 125I-labelled Protein A (Amersham) in 1% Marvel/PBS and autoradiography.
Production of SIV p27-specific MAbs. Mice were injected twice intraperitoneally with 2 to 5 ~tg of SIV p27-TAG as SMAA complexes (as 200 id aliquots of 0-5 % w/v suspension of the complexes) with a gap of 3 to 4 weeks between the first and second injections. Ten days after the second injection, mice were bled and the sera assayed for the presence of anti-p27 antibodies. Twenty-one days after the second immunization mice were boosted by tail vein immunization with 2 to 5 ~tg of purified p27-TAG. Four days later the mice were euthanized, the splenocytes fused with SP2/0-Ag-!4 cells and hybridomas secreting MAbs specific for p27, as assayed by ELISA and dot blotting using recombinant p27-TAG and on Western blots of SIV-infected ce|l lysates, were isolated using the methodology described in detail elsewhere (Randall et al., 1987) .
Results

Construction of expression vectors
Prokaryotic organisms are in many ways suitable expression systems for the production of antigens. They are inexpensive, give high protein yields and are well characterized, so that there are a large number of bacterial promoters and versatile vectors available. Important drawbacks of these systems are the lack of glycosylation and the inability to form disulphide bridges (for review see Vlak & Keus, 1990) which, in some instances, make the expressed proteins more sensitive to a proteolytic degradation. We have used for expression of tag-linked SIV antigens the E. coli expression vector pGEX-2T (Fig. 1 ) described by Smith & Johnson (1988) . In this system, recombinant proteins are expressed as a fusion protein linked to the C terminus of GST and can be easily purified by affinity chromatography on immobilized glutathione. The GST gene is under the control of the lac promoter and can therefore be induced by IPTG. The pGEX-2T vector was also designed so that the GST carrier polypeptide can be cleaved from the fusion protein by digestion with thrombin.
A region of the SIV gag gene encoding the major core protein p27 was specifically amplified from plasmid pBK28-SIV DNA (Kornfeld et al., 1987) using PCR and the p27 PCR product was ligated into pSV2X3 resulting in plasmid pSV27 (Fig. 1 ). An oligonucleotide linker encoding the tag antigen, i.e. 14 amino acids of SV5 P and V proteins (Fig. 2) recognized by MAb SV5-P-k (Southern et al., 1991) , was inserted at the 3' terminus of p27 gene, yielding plasmid pSV27T. In order to insert the hybrid gene into pGEX-2T, the BclI site at the 5' end of the p27-TAG gene had to be regenerated by PCR amplification from pSV27T using p27BACK primer and the negative strand of the tag DNA linker as primers. The amplified sequences were inserted into BamHI and EcoRI sites of pGEX-2T.
Similarly, sequences coding for glycoprotein gp110 of SIV env were PCR-amplified from pKB28-SIV plasmid, coupled to the tag linker and inserted into pGEX-2T for the expression of GST-gp110-TAG fusion protein. The tag DNA linker was also inserted alone into pGEX-2T for the production of GST-TAG (not shown).
Expression of tag-linked SIV antigens and construction of SMAA complexes
SIV p27-TAG was expressed in E. coli as a fusion protein with GST. The expression of GST-p27-TAG was induced by addition of IPTG into bacterial cultures transformed with pGEX27T plasmid. On SDS-PAGE of disrupted bacterial pellet, GST-p27-TAG gave a prominent band migrating at about 52K (Fig. 3, lane L) . For the purification of GST-p27-TAG, bacteria were lysed by incubation with lysozyme and IPB followed by vigorous sonication. The sonicated lysate was centrifuged and the supernatant used for either glutathioneaffinity column purification of GST-p27-TAG or construction of SMAA complexes.
Two approaches were taken to construct SMAA complexes. In the first, SMAA complexes were prepared by an incubation of SV5-P-k saturated S. aureus particles with a soluble antigen preparation. The resulting SMAA complexes containing GST-p27-TAG were washed several times in IPB and PBS, and analysed by SDS-PAGE (Fig. 3, lane 1) . Coomassie blue-stained gel shows highly purified GST-p27-TAG protein migrating between the heavy and light immunoglobulin chains of SV5-P-k antibody. All three bands are roughly in equimolar amounts confirming that SV5-P-k antibody in SMAA complexes was saturated with the antigen. In order to remove the GST domain of the fusion protein from the surface of the complexes, the GST-p27-TAGcontaining SMAA complexes were incubated with thrombin and the cleaved complexes were analysed by gel electrophoresis (Fig. 3, lane 2) . The gel revealed a peptide doublet released from the 'shaved' SMAA complexes. The reason for obtaining two species after the thrombin digestion of GST-p27-TAG is obscure, as amino acid sequence analysis of p27-TAG did not reveal any other recognition sites for thrombin.
To confirm that the polypeptides incorporated in the SMAA complexes above were indeed SIV p27 linked to the oligopeptide tag, disrupted SMAA complexes were analysed by Western blot transfer. Incubation with both anti-tag (SV5-P-k) and anti-p27 (KK33) MAbs resulted in a strong signal on the autoradiogram corresponding to the Mr of p27-TAG (Fig. 4, lanes 2) . Shorter exposure of the same transfer showed that both bands of the doublet were recognized by both MAbs (not shown). The Western blot also revealed distinct faster-migrating bands detected with SV5-P-k (Fig. 4b, lanes 1 and 2) and partially with KK33 (Fig. 4a, lane 1) MAbs. These bands were products of a proteolytic degradation and assembled into SMAA complexes via the oligopeptide tag. Taking advantage of the affinity of GST for its natural substrate glutathione, we decided to avoid the contamination of SMAA complexes with degraded p27- 
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T A G by prior purification of G S T -p 2 7 -T A G fusion protein on a glutathione affinity column. Crude bacterial lysate was incubated with glutathione coupled to agarose beads. Beads with adsorbed G S T -p 2 7 -T A G were loaded into a column and thoroughly washed with IPB and PBS. As G S T -p 2 7 -T A G bound to the beads via the G S T end of the fusion protein, the washes removed all d e g r a d a t i o n products lacking the G S T domain. The protein p27-T A G was then released from the column by cleavage with t h r o m b i n (Fig. 3, lane 3) . Note that the t h r o m b i n cleavage of G S T -p 2 7 -T A G a d s o r b e d to the column again released a p 2 7 -T A G doublet. Purified p 2 7 -T A G readily assembled into S M A A complexes (Fig. 3, lane 4) , this time without c o n t a m i n a t i o n with the d e g r a d e d species (Fig. 4 a and b, lanes 4) . Thus, we have developed a straightforward procedure for producing a relatively large a m o u n t of tag-based S M A A complexes using SV5-P-k M A b and a bacterially expressed tag-linked antigen. In order to construct S M A A complexes containing SIV g p l l 0 , bacteria were transformed with p l a s m i d p G E X 1 1 0 T and the expression of G S T -g p 1 1 0 -T A G was induced by I P T G . W e were not able to observe any p r o m i n e n t band after S D S -P A G E corresponding to G S T -g p 1 1 0 -T A G in the induced bacterial lysates (not shown). Western blot analysis of four i n d e p e n d e n t clones carrying p G E X 1 1 0 T with anti-tag M A b showed that the vast majority of G S T -g p l l 0 -T A G was proteolytically degraded. Fig. 1 . Construction of pGEX27T expression vector. The fusion protein p27 DNA was amplified by PCR from pBK28-SIV plasmid. The PCR product was treated with polynucleotide kinase and the Klenow fragment of DNA polymerase, digested with BclI and the BclI/blunt fragment was ligated between the unique BamHI and Sinai sites of the pSV2X3 (Hanke et al., 1990) polylinker. The resulting plasmid pSV27 was cleaved with BamHI and XhoI for the ligation of the tag linker (Fig. 2) . In order to regenerate BclI site at the 5' end of the hybrid gene, p27-TAG DNA was amplified by PCR from pSV27T using p27BACK and the negative strand of the tag linkers as primers. Amplified p27-TAG DNA was digested with BclI and EcoRI and inserted into BamHI and EcoRI sites of pGEX-2T yielding pGEX27T. Plasmid pGEX 110T was constructed using the same sequence of reactions. Plasmid pGEXTAG was constructed by an insertion of an EcoRI-digested tag linker between the unique BamHI and EcoRI sites of pGEX-2T. induced by immunization with SMAA complexes containing recombinant SIV p27-TAG was assayed against SIVmac251-infected cell lysates. SIV-infected cell lysates were subjected to electrophoresis through a 15 % polyacrylamide/DATD mini-slab gel, transferred onto a nitrocellulose filter and incubated with corresponding ascitic fluids. The presence of bound MAbs was detected by l zsI-labelled Protein A followed by autoradiography, p27-specific (KK33) MAb (lane 3) was used as a positive control, and TAG-specific (SV5-P-k) (lane 1) and irrelevant IgG2a (PIV2-HN-2a) (lane 2) MAbs served as negative controls.
Isolation of p27-specific MAbs
SMAA complexes containing recombinant SIV p27-TAG were used to immunize mice for the production of p27-specific MAbs. Sera taken from immunized mice were tested for the presence of antibodies binding to p27-TAG and GST-TAG in a radioimmunoassay. The antibody titre against p27-TAG was significantly higher than that against GST-TAG (not shown) demonstrating that serum antibodies recognized the p27 portion of p27-TAG fusion protein rather than the tag itself. This is in accordance with our previous results. We have shown that immunization with SMAA complexes resulted in relatively less antibodies being produced to the epitope bound to the antibodies of SMAA complexes compared with the other antigenic determinants on the protein . Splenocytes from immunized mice were isolated and used for generation of hybridoma cells secreting SIV p27-specific antibodies. Seven independent cell lines producing antibodies to p27 have been isolated in this manner. Fig. 5 shows the reactivities of these MAbs on a Western blot transfer of SIV-infected cell lysates. All MAbs recognized native p27 and were, apart from SIV-27-d, detected by 125I-labelled Protein A. MAb SIV-27-d appears negative on Fig. 5 because it is of the IgG1 isotype and murine IgG1 has a low affinity for Protein A. Positive binding of SIV-27-d was demonstrated using polyclonal rabbit anti-mouse antibodies followed by l z5I-labelled Protein A (data not shown). Isotypes of the other p27-specific MAbs are: IgG2a (a, b, e and f), IgG2b (c) and IgG3 (g) (data not shown). The Western blot of p27-specific MAbs also shows weakly reacting bands of larger and smaller Mr values than p27, which probably correspond to other products of the gag polyprotein processing (Ferns et al., 1987) . The banding patterns suggest that there are three groups of MAbs (b and c same as KK33; e and f; a and g), although this remains to be confirmed. None of the p27-specific MAbs reacted with SV5 proteins, i.e. did not recognize the tag peptide (data not shown). The isolation of p27-specific MAb demonstrates the general use of tag-based SMAA complexes for producing immunological reagents.
Discussion
We have shown that the construction of tag-based SMAA complexes is a feasible approach to achieving human multivalent vaccines. Tag-based SMAA complexes are an attractive alternative for human vaccine design and we envisage a universal vaccine core of a human or humanized tag-specific MAb attached to a suitable solid matrix, to which tag-linked antigens of choice are bound.
A panel of MAbs against the paramyxovirus SV5 was previously isolated in our laboratory . Binding of one MAb, SV5-P-k, to SV5 P and V proteins was in a radioimmunoassay successfully competed with a synthetic peptide (Southern et al., 1991) . The originally identified nonapeptide was rather hydrophobic (Fig. 2) . In order to expose the oligopeptide tag on the surface of proteins to which it is attached and thus make it more amenable to antibody interaction, we expanded the tag by five amino acids including hydrophilic Ser and Thr at the carboxyl end. Indeed, the 14-amino acid tag maintained its antigenicity, i.e. its ability to be recognized by SV5-P-k antibody, under both denaturing and non-denaturing conditions when linked to the C termini of several larger proteins: SIV p27 and gpll0, and GST. In addition, the peptide tag has been linked to a bacterially expressed Fv antibody fragment specific for lysozyme. Attachment of the tag did not prevent secretion of the Fv fragment into the periplasmic space of bacteria; Fv-TAG recognized its natural antigen in ELISA and could be detected by SV5-P-k MAb (T. Hanke, R. Hawkins & G. Winter, MRC Laboratory of Molecular Biology, Cambridge, U.K., unpublished observations). Thus, we have shown that addition of a short peptide derived from SV5 to other proteins does not affect its antigenicity, and that the strong interaction between the tag antigen and a tagspecific antibody can be used to assemble protein antigens into SMAA complexes.
The expression of antigens with the peptide tag attached to their C termini as fusion proteins with GST proved very useful for the selective incorporation of the full-size p27-TAG into SMAA complexes. The fusion proteins degraded at their N terminus (the GST domain) were washed off the glutathione affinity column, whereas all the species cleaved off the column by thrombin and degraded at their C terminus (TAG) were not bound by SV5-P-k MAbs present in SMAA complexes. Thus, C terminus-tagged non-degraded antigens were purified for the preparation of SMAA complexes from crude bacterial lysates in a two-step procedure. As we have shown by the isolation of SIV p27-specific monoclonal antibodies, these SMAA complexes can serve as a simple means for raising MAbs in laboratory animals.
An efficient multivalent subunit vaccine will have to include glycoproteins in its formula in order to induce neutralizing serum antibodies that recognize surface structures of pathogens. Here, we expressed part of SIV env gene in a bacterial expression system as GST-gp110-TAG ; however, the produced fusion protein was rapidly degraded. The absence of glycosylation in bacteria presumably affects the protein folding and consequently the protein's stability and resistance to proteolytic cleavage. In order to express the gpl 10-TAG glycoprotein in eukaryotic cells, we are currently constructing recombinant adenovirus vectors carrying the gpll0-TAG gene. It will be of interest to determine whether the oligopeptide tag retains its antigenicity when linked to a glycoprotein, and how the presence of the tag influences the folding, processing and immunogenicity of the glycoprotein itself.
SMAA complexes used as human vaccines will have to include human antibodies in order to avoid immune responses directed against the antibody component of the complexes. Although human hybridoma technology is not yet at the stage of routine production of human MAbs, recombinant DNA techniques offer a solution. It is possible to construct hybrid antibodies by substituting the genetic information for antigen-binding regions of human heavy and light chains with their rodent counterparts of desired antigen specificity (Winter & Milstein, 1991) . The whole humanized antibody can then be produced in rat myeloma cells (Reichmann et al., 1988; Verhoeyen et al., 1988; Tempest et al., 1991) or more effectively in Chinese hamster ovary cells (Page & Sydenham, 1991) . However, if the Fc portion of a MAb were dispensable for efficient uptake and presentation of antigens by antigen-presenting cells, Fab or Fv fragments could substitute for the whole antibody in SMAA complexes. Incorporation of Fab or Fv fragments into SMAA complexes would have the advantages of a reduced chance of adverse immune reactions and the availability of bacterial expression systems. The cloning of the variable domains of SV5-P-k MAb and their complete reshaping is currently under way. This work was supported by a grant from the AIDS Directed Programme of the Medical Research Council, U.K.
